X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.6% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares X4 Pharmaceuticals and Adaptive Biotechnologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| X4 Pharmaceuticals | $2.56 million | 16.06 | -$101.17 million | ($0.19) | -1.24 |
| Adaptive Biotechnologies | $178.96 million | 6.17 | -$159.49 million | ($1.09) | -6.82 |
Volatility and Risk
X4 Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for X4 Pharmaceuticals and Adaptive Biotechnologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| X4 Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Adaptive Biotechnologies | 0 | 0 | 5 | 0 | 3.00 |
X4 Pharmaceuticals presently has a consensus price target of $2.83, indicating a potential upside of 1,098.53%. Adaptive Biotechnologies has a consensus price target of $9.40, indicating a potential upside of 26.51%. Given X4 Pharmaceuticals’ higher possible upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than Adaptive Biotechnologies.
Profitability
This table compares X4 Pharmaceuticals and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| X4 Pharmaceuticals | N/A | -236.19% | -75.14% |
| Adaptive Biotechnologies | -89.12% | -64.65% | -26.45% |
Summary
Adaptive Biotechnologies beats X4 Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
